tibenzonium iodide: Negwer reference is for tibenzonium hydroxide; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 6918582 |
| CHEMBL ID | 2107065 |
| SCHEMBL ID | 563722 |
| MeSH ID | M0061699 |
| Synonym |
|---|
| antoral |
| D02712 |
| tibezonium iodide (inn) |
| diethylmethyl(2-((4-(p-(phenylthio)phenyl)-3h-1,5-benzodiazepin-2-yl)thio)ethyl)ammonium iodide |
| ethanaminium, n,n-diethyl-n-methyl-2-((4-(4-(phenylthio)phenyl)- 3h-1,5-benzodiazepin-2-yl)thio)-, iodide |
| thiabenzazonium iodide |
| rec-15/0691 |
| einecs 259-284-1 |
| nsc 308905 |
| tibenzonio ioduro [dcit] |
| iodure de tibezonium [inn-french] |
| ethanaminium, n,n-diethyl-n-methyl-2-((4-(4-(phenylthio)phenyl)-3h-1,5-benzodiazepin-2-yl)thio)-, iodide |
| tibezonii iodidum [inn-latin] |
| 2-(beta-(n-diethylamino)ethylthio)-4-(p-phenylthio)phenyl-3h-1,5-benzodiazepine methiodide |
| ioduro de tibezonio [inn-spanish] |
| tibezonium iodide [inn] |
| tibenzonium iodide |
| ethanaminium,n-diethyl-n-methyl-2-[[4-[4-(phenylthio)phenyl]-3h-1,5-benzodiazepin-2-yl]thio]-, iodide |
| thiabenzazonium |
| nsc-308905 |
| diethylmethyl[2-[[4-[p-(phenylthio)phenyl]-3h-1,5-benzodiazepin-2-yl]thio]ethyl]ammonium iodide |
| tibezonium iodide |
| 54663-47-7 |
| ioduro de tibezonio |
| tibenzonio ioduro |
| iodure de tibezonium |
| tibezonii iodidum |
| unii-e9p274ajew |
| e9p274ajew , |
| CHEMBL2107065 |
| tibezonium iodide [who-dd] |
| tibezonium iodide [mi] |
| tibezonium iodide [mart.] |
| SCHEMBL563722 |
| AC-24504 |
| AKOS025401688 |
| HY-131554 |
| tibezonium (iodide) |
| DTXSID60905128 |
| DB13702 |
| Q7800429 |
| BCP12853 |
| diethyl-methyl-[2-[[2-(4-phenylsulfanylphenyl)-3h-1,5-benzodiazepin-4-yl]sulfanyl]ethyl]azanium;iodide |
| CS-0136629 |
| Excerpt | Relevance | Reference |
|---|---|---|
| "It is clinically important to deliver a sustained-release mucoadhesive dosage of local anesthetic and antimicrobial agents for pain control." | ( Development and optimization of tibezonium iodide and lignocaine hydrochloride containing novel mucoadhesive buccal tablets: a pharmacokinetic investigation among healthy humans. Hanif, S; Irfan, M; Mahmood, A; Minhas, MU; Sarfraz, RM; Syed, MA, 2021) | 0.62 |
| "Therefore, the sustained release mucoadhesive dosage form of TBN and LGN can be an effective and alternative option to conventional delivery." | ( Development and optimization of tibezonium iodide and lignocaine hydrochloride containing novel mucoadhesive buccal tablets: a pharmacokinetic investigation among healthy humans. Hanif, S; Irfan, M; Mahmood, A; Minhas, MU; Sarfraz, RM; Syed, MA, 2021) | 0.62 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 3 (75.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (20.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 4 (80.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||